Design aspects of COVID-19 treatment trials: Improving probability and time of favourable events

11/27/2020
by   Jan Beyersmann, et al.
0

As a reaction to the pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a multitude of clinical trials for the treatment of SARS-CoV-2 or the resulting corona disease (COVID-19) are globally at various stages from planning to completion. Although some attempts were made to standardize study designs, this was hindered by the ferocity of the pandemic and the need to set up trials quickly. We take the view that a successful treatment of COVID-19 patients (i) increases the probability of a recovery or improvement within a certain time interval, say 28 days; (ii) aims to expedite favourable events within this time frame; and (iii) does not increase mortality over this time period. On this background we discuss the choice of endpoint and its analysis. Furthermore, we consider consequences of this choice for other design aspects including sample size and power and provide some guidance on the application of adaptive designs in this particular context.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
05/28/2020

Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?

Very recently the new pathogen severe acute respiratory syndrome coronav...
research
06/09/2020

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Introduction: Endpoint choice for randomized controlled trials of treatm...
research
10/29/2021

Statistical Review of Animal trials – A Guideline

Examinations of any experiment involving living organisms require justif...
research
01/24/2019

Seamless phase II/III clinical trials using early outcomes for treatment or subgroup selection: Methods and aspects of their implementation

Adaptive seamless designs combine confirmatory testing, a domain of phas...
research
07/31/2020

Causal inference methods for small non-randomized studies: Methods and an application in COVID-19

The usual development cycles are too slow for the development of vaccine...
research
12/19/2020

Revisiting ICH E9 (R1) during the COVID-19 pandemic

The current COVID-19 pandemic poses numerous challenges for ongoing clin...

Please sign up or login with your details

Forgot password? Click here to reset